Ablynx - Publication in accordance with §14 of the Belgian Law

 

Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Millennium Group Management LLC on 27 November 2017.

Millennium Group Management LLC notified Ablynx that it has crossed downward the lowest threshold on 21 November 2017.

 

The notification contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights; downward crossing of the lowest threshold
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement: Millennium Group Management LLC
  • Date on which threshold is crossed: 21 November 2017
  • Threshold that is crossed: 3%
  • Denominator: 74,720,644
  • Details of the notification: - (no details required when downward crossing the lowest threshold)
  • Chain of controlled undertakings through which the holding is effectively being held: Millennium International Management LP and Integrated Core Strategies (Europe) Sarl are ultimately controlled by Millennium Group Management LLC.
  • Additional information: Millennium International Management LP is a discretionary investment manager of various trading vehicles that can exercise the voting rights at its discretion in the absence of specific instructions.

 

More information is provided in the transparency notification. Full versions of the transparency notifications are available on Ablynx website, under the section Investors.

 

The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

Note

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?